Cargando…

Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation

Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Suslova, Tatiana E., Sitozhevskii, Alexei V., Ogurkova, Oksana N., Kravchenko, Elena S., Kologrivova, Irina V., Anfinogenova, Yana, Karpov, Rostislav S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283519/
https://www.ncbi.nlm.nih.gov/pubmed/25601838
http://dx.doi.org/10.3389/fphys.2014.00501
_version_ 1782351276330188800
author Suslova, Tatiana E.
Sitozhevskii, Alexei V.
Ogurkova, Oksana N.
Kravchenko, Elena S.
Kologrivova, Irina V.
Anfinogenova, Yana
Karpov, Rostislav S.
author_facet Suslova, Tatiana E.
Sitozhevskii, Alexei V.
Ogurkova, Oksana N.
Kravchenko, Elena S.
Kologrivova, Irina V.
Anfinogenova, Yana
Karpov, Rostislav S.
author_sort Suslova, Tatiana E.
collection PubMed
description Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet activation in MetS and T2DM comprise insulin resistance, hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity in MetS patients can play a central role in the manifestation of platelet hyperactivation. Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets. This review provides data on the insulin effects in platelets. Decrease in a number and sensitivity of the insulin receptors on platelets in T2DM can cause platelet hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review presents data suggesting an ability of platelets to synthesize humoral factors stimulating thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers of T2DM and cardiovascular complications and are involved in the development of dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated signaling pathway in the effects of cytokines on platelet aggregation. The effects of the proinflammatory cytokines on functional activity of platelets are demonstrated.
format Online
Article
Text
id pubmed-4283519
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-42835192015-01-19 Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation Suslova, Tatiana E. Sitozhevskii, Alexei V. Ogurkova, Oksana N. Kravchenko, Elena S. Kologrivova, Irina V. Anfinogenova, Yana Karpov, Rostislav S. Front Physiol Physiology Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet activation in MetS and T2DM comprise insulin resistance, hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity in MetS patients can play a central role in the manifestation of platelet hyperactivation. Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets. This review provides data on the insulin effects in platelets. Decrease in a number and sensitivity of the insulin receptors on platelets in T2DM can cause platelet hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review presents data suggesting an ability of platelets to synthesize humoral factors stimulating thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers of T2DM and cardiovascular complications and are involved in the development of dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated signaling pathway in the effects of cytokines on platelet aggregation. The effects of the proinflammatory cytokines on functional activity of platelets are demonstrated. Frontiers Media S.A. 2015-01-05 /pmc/articles/PMC4283519/ /pubmed/25601838 http://dx.doi.org/10.3389/fphys.2014.00501 Text en Copyright © 2015 Suslova, Sitozhevskii, Ogurkova, Kravchenko, Kologrivova, Anfinogenova and Karpov. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Suslova, Tatiana E.
Sitozhevskii, Alexei V.
Ogurkova, Oksana N.
Kravchenko, Elena S.
Kologrivova, Irina V.
Anfinogenova, Yana
Karpov, Rostislav S.
Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation
title Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation
title_full Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation
title_fullStr Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation
title_full_unstemmed Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation
title_short Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation
title_sort platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cgmp- and no-dependent mechanisms in the insulin-mediated platelet aggregation
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283519/
https://www.ncbi.nlm.nih.gov/pubmed/25601838
http://dx.doi.org/10.3389/fphys.2014.00501
work_keys_str_mv AT suslovatatianae platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation
AT sitozhevskiialexeiv platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation
AT ogurkovaoksanan platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation
AT kravchenkoelenas platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation
AT kologrivovairinav platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation
AT anfinogenovayana platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation
AT karpovrostislavs platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation